Home » Baxter’s Immunodeficiency Drug Reveals Positive Results in Phase III Study
Baxter’s Immunodeficiency Drug Reveals Positive Results in Phase III Study
Baxter International revealed positive results from a late-stage study of HyQ to treat primary immunodeficiency, whereby the rate of bacterial infection was much lower than the threshold level.
RTTNews
RTTNews
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May